Skip to content
argenx logo — United in our commitment to improve the lives of patients

argenx

United in our commitment to improve the lives of patients

Founded 2008 United States Boston, United States 2363 employees IPO Total: $3.55B Biotechnology, Health and Wellness +1

General Information

Company Name argenx
Founded Year 2008
Location United States Boston, United States
Founders / Decision Makers
Team member Team member
Employees 2363
Industries Biotechnology, Health and Wellness, Pharmaceutical
Funding Stage IPO
Business Model B2B2C, B2B
Revenue Model Product Sales, Licensing

BounceWatch is an independent company data service, not affiliated with argenx. To contact argenx, visit argenx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does argenx compare?

A PDF of argenx and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting argenx soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

New Partnership Oct 28, 2026

argenx collaborates with academic scientists through its Immunology Innovation Program to advance research.

Event Participation Oct 22, 2026

argenx is presenting new data from the Phase 3 ALKIVIA study at the American College of Rheumatology Convergence.

About argenx

argenx, a prominent name in the Biotechnology and Health and Wellness industries, is firmly positioned as a global leader in immunology. Established in 2008, the company is headquartered in the United States and is driven by its slogan, United in our commitment to improve the lives of patients.

Specializing in severe autoimmune diseases, argenx collaborates with academic leaders via its Immunology Innovation Program (IIP), effectively translating immunology innovations into a robust portfolio of pioneering antibody-based therapies.

A noteworthy aspect of its financial trajectory is the substantial €979.60M Post-IPO Equity investment secured on 19 July 2023. This influx of capital is anticipated to bolster its R&D capabilities and expedite the development of its immunology solutions.

For investors, argenx represents a strategic opportunity to participate in the future of biotechnological advancements tailored towards transformative patient outcomes in autoimmune diseases.

Business keywords: Immunology, Autoimmune Diseases, Antibody-based Medicines, Immunotherapy, Myasthenia Gravis, Pemphigus Vulgaris, Immune Thrombocytopenia, Acute Myeloid Leukemia, High-risk Myelodysplastic Syndromes, Chronic Inflammatory Demyelinating Polyneuropathy, Oncology, Rare Diseases, Immunology Innovation Program, Academic Research Partnerships, Severe Autoimmune Diseases

Services & Products

Research and Development
Product Pipeline Development
Partnership in Antibody Innovation

Target Customers

Patients with Autoimmune Diseases Healthcare Professionals Academic Collaborators

Funding Rounds & Investors (13)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity $1.10B -
01 Jul 2023
Post-IPO Equity $5.67M 1
Old Mission Capital
01 Feb 2023
Post-IPO Equity €637.00M -
01 Mar 2022
Post-IPO Equity €830.30M -
01 Feb 2021
Post-IPO Equity €502.00M -
01 Nov 2019
Post-IPO Equity €250.00M -
01 Sep 2018
IPO $100.00M -
01 May 2017
Post-IPO Equity €30.00M 3
DAFNA Capital Management, LLC, MPM BioImpact +1
01 Jun 2016
Grant €1.50M -
01 May 2015
IPO €41.77M -
01 Jul 2014

View All 13 Funding Rounds

argenx Alternatives & Competitors

View All Alternatives
argenx vs

Framing the future of autoimmune diseases

Post-IPO Equity
163 employees
Biotechnology, Health Care
argenx vs
Genmab
Genmab Denmark

Differentiated human antibody therapeutics for the treatment of cancer

IPO
3102 employees
Biotechnology, Pharmaceutical
argenx vs
REGENXBIO
REGENXBIO United States

Seeking to improve lives through the curative potential of gene therapy.

IPO
389 employees
Biopharma, Biotechnology

FAQ About argenx

United in our commitment to improve the lives of patients
argenx was founded in 2008.
argenx is headquartered in Boston, United States.
argenx operates in Biotechnology, Health and Wellness and Pharmaceutical. Its work centres on Immunology, Autoimmune Diseases, Antibody-based Medicines and Immunotherapy. Its customers include Patients with Autoimmune Diseases, Healthcare Professionals and Academic Collaborators.
argenx has a B2B2C and B2B business model. Its revenue comes from Product Sales and Licensing.
argenx has approximately 2363 employees.
argenx has completed 13 funding rounds, raising a total of $3.55B. The latest funding stage is IPO.
argenx offers: Research and Development, Product Pipeline Development, Partnership in Antibody Innovation.
Top alternatives and competitors to argenx include Viridian Therapeutics, Inc., Genmab, REGENXBIO, Takeda Oncology, Innolake Biopharm. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
argenx and Viridian Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for argenx, https://bouncewatch.com/company/argenx, updated 6 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout